NEWS CENTER

PRESS RELEASES

02.06.2020
Epic Sciences to Present New Data Demonstrating Expanded Clinical Utility of AR-V7 at 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium
AN DIEGO, Calif., February 6, 2020 – Epic Sciences, Inc. announced today it will present two abstracts at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium to be held in San Francisco, February 13 – 15, 2020. The abstracts feature two analyses of the PROPHECY trial cohort. One abstract evaluates the androgen-receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) as a predictor of resistance to anti-androgen therapy. The second abstract reports new data on CTC-based biomarkers of chromosomal instability and small-cell neuroendocrine transformation and their association to resistance to anti-androgen therapy. Read Full Release
12.05.2019
Epic Sciences to Present New Data Showing Feasibility of its Liquid Biopsy Test in Breast Cancer
Epic Sciences, Inc. today announced the presentation of new data demonstrating the feasibility of using its proprietary technology for the detection and characterization of rare cells to guide the treatment of breast cancer. The data to be presented show the use of Epic Sciences’ liquid biopsy test to profile circulating tumor cells (CTCs) based on morphological features, protein marker expression and genomic alterations. Epic Sciences will present the data at the 2019 San Antonio Breast Cancer Symposium held on December 10 – 14, in San Antonio, Texas. Read Full Release
12.03.2019
Epic Sciences Expands Executive Leadership Team - Appoints Joel Smith as Chief Financial Officer & General Counsel
Epic Sciences, Inc. today announced the appointment of Joel Smith as its chief financial officer and general counsel. Mr. Smith joins the company’s impressive roster of industry veterans. “Joel’s appointment comes at a pivotal time for Epic Sciences as we build upon the commercial success of our AR-V7 test and remain highly focused on bringing transformative clinical solutions to new, unmet cancer indications,” said Lloyd Sanders, president and CEO at Epic Sciences. “His legal expertise in the commercialization of medical technologies, coupled with his background in molecular biology and economics, make him well-suited for this role as we expand our suite of functional cell profiling technologies to advance precision medicine for patients and drug developers.” Read Full Release
05.30.2019
Published Study Demonstrates Feasibility of a Blood Test to Predict Disease Progression and Metastasis in Localized Prostate Cancer
Epic Sciences announced the publication of a six-year study demonstrating the clinical applicability of circulating tumor cells (CTCs) to predict prostate cancer progression and metastasis. The study, conducted in collaboration with the University of Michigan utilizing Epic’s CTC technology platform, is published in the Journal of Clinical Oncology Precision Oncology. Read Full Release

NEWS

01.15.2020 | genomeweb
Circulating Tumor Cell Collection, Analysis Methods Make Headway in 2019
NEW YORK – 2019 was a busy year for circulating tumor cell (CTC) capture and detection, as academic and commercial groups continued to develop novel techniques to extract and purify CTCs for diagnosing several cancers, and accelerated their efforts to bring these technologies to the clinic. Notably, companies are increasingly exploring CTC capture methods alongside circulating tumor DNA (ctDNA) purification and analysis tools to distinguish themselves from the crowded ctDNA detection space and potentially unlock additional liquid biopsy applications. Read Full Article
12.27.2019 | Fierce Biotech
Blood Testing Nears a Turning Point as the Evidence Becomes Undeniable
Blood has always held the keys to our bodies’ health: it helps carry nutrients in and waste out, and interrogating it can provide solace when we are well and answers when we are sick. Blood testing is ubiquitous, but it’s clear its possibilities are unfulfilled. Through different methods and modalities, these diagnostics promise to be a more accessible, less invasive, smarter, cheaper and a comprehensive way to gather knowledge about what’s going on under the skin—whether in a doctor’s office, at home or within a clinical laboratory. Read Full Article
12.19.2019 | American Journal of Managed Care: AJMC
Personalizing Breast Cancer: How Liquid Biopsy Testing for ctDNA, CTCs Can Promote Preventive Care
Two abstracts on liquid biopsy tests revealed the potential of analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in promoting heightened decision-making by clinicians for patients with early-stage and metastatic breast cancer. Read Full Article
07.01.2019 | Genetic Engineering & Biotechnology News
Liquid Biopsy Technologies Diversify in Expanding CTC Field
The field of circulating tumor cells (CTCs) is exploding with competing technologies, all offering different approaches to isolating and characterizing CTCs from blood. CTCs are incredibly rare. Out of ten billion blood cells, only a handful may be CTCs. They are believed to be the mechanism behind cancer metastasis, and there is a great deal of interest in using them to diagnose, monitor, and predict the course of the disease. Read Full Article

EVENTS

SABCS 2019
The Epic Sciences team will be attending and exhibiting at the San Antonio Breast Cancer Symposium - Booth #626 - in San Antonio, TX from December 10 - December 14, 2019. More Info
ASCO 2019
The Epic Sciences team will be attending ASCO 2019 Annual Meeting - Booth #2066 - in Chicago, IL from May 31 - June 4, 2019. More Info
AACR 2019
The Epic Sciences team attended AACR Annual Meeting - Booth #4455 - in Atlanta, GA from March 29 - April 3, 2019. More Info
ASCO GU 2019
The Epic Sciences team attended the ASCO Genitourinary Cancer Symposiums Annual Meeting in San Francisco, CA from February 14 - 16, 2019. More Info